ASH 2018 | A personalized prediction model to risk stratify patients with MDS
Aziz Nazha
Myelodysplastic syndrome (MDS) patients have very heterogeneous outcomes in terms of overall survival. Here, Aziz Nazha, MD, of the Cleveland Clinic, Cleveland, OH, discusses a personalized prediction model that uses clinical-, molecular-, and transplant-related data predict the probability of survival for individual MDS patients, aiding HCPs and patients in their decision-making prior to transplant. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Similar topics
Related videos

Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS
Saar Gill

MDS news from ASH 2018
Alan List

Results of MEDALIST: luspatercept reduces transfusion burden in MDS
Alan List

Future biomarkers for MDS
Alan List

Updates from ASH 2018 in MDS therapy
Guillermo Garcia-Manero
More from Aziz Nazha